Emtricitabine News and Research

RSS
Emtricitabine, also known as Emtriva or FTC, is a type of medicine called a nucleoside reverse transcriptase inhibitor (NRTI). NRTIs block reverse transcriptase, a protein that HIV needs to make more copies of itself. Emtricitabine in capsule form was approved by the FDA on July 2, 2003, for use with other antiretroviral agents in the treatment of HIV infection in adults. Emtricitabine oral solution was approved by the FDA on September 28, 2005, and is now approved for use with other anti-HIV drugs in the treatment of HIV-1 infection in patients older than 3 months of age. This medicine does not cure or prevent HIV infection or AIDS and does not reduce the risk of passing the virus to other people.
Study: Antiretroviral drugs may prevent HIV infection in women

Study: Antiretroviral drugs may prevent HIV infection in women

VOICE clinical study for testing the efficacy of two HIV prevention strategies

VOICE clinical study for testing the efficacy of two HIV prevention strategies

MSD's ISENTRESS approved by the EU Commission for treating HIV-1 infection in adult patients

MSD's ISENTRESS approved by the EU Commission for treating HIV-1 infection in adult patients

Phase II VICTOR-E1 clinical study results reported

Phase II VICTOR-E1 clinical study results reported

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV

Schering-Plough expands Vicriviroc study in treatment-naive patients with HIV

Early retroviral use best for AIDS patients with serious complications

Early retroviral use best for AIDS patients with serious complications

Early use of antiretroviral treatment improves survival rate of HIV patients

Early use of antiretroviral treatment improves survival rate of HIV patients

Gilead Sciences announces notification of ANDA filing for Atripla

Gilead Sciences announces notification of ANDA filing for Atripla

Mylan's Matrix receives tentative FDA approval under PEPFAR for generic Truvada

Mylan's Matrix receives tentative FDA approval under PEPFAR for generic Truvada

Gilead initiates phase III trial of Elvitegravir

Gilead initiates phase III trial of Elvitegravir

Researchers to compare common ARV as a pill and vaginal gel in unique HIV prevention study

Researchers to compare common ARV as a pill and vaginal gel in unique HIV prevention study

Anti-retrovirals given daily before and after exposure to HIV prevent vaginal transmission AIDS virus

Anti-retrovirals given daily before and after exposure to HIV prevent vaginal transmission AIDS virus

HIV drug resistance risk in mothers reduced by tenofovir/emtricitabine with nevirapine during labor

HIV drug resistance risk in mothers reduced by tenofovir/emtricitabine with nevirapine during labor

Pre-exposure prophylaxis for HIV infection

Pre-exposure prophylaxis for HIV infection

Entecavir can compromise HIV treatment

Entecavir can compromise HIV treatment

Drug warning prompts treatment changes for those infected with hepatitis B and HIV

Drug warning prompts treatment changes for those infected with hepatitis B and HIV

FDA approves Atripla for the treatment of HIV-1 infection in adults

FDA approves Atripla for the treatment of HIV-1 infection in adults

FDA approves Atripla three-drug combination tablet for treatment of HIV-1

FDA approves Atripla three-drug combination tablet for treatment of HIV-1

Approval of fixed-dose combination treatments for HIV-1 infection

Approval of fixed-dose combination treatments for HIV-1 infection